WebBrexafemme FEP Clinical Criteria Patients who have filled at least a 1-day supply of fluconazole in the last 30 days are exempt from these Prior Authorization (PA) requirements. WebBrexafemme ® (ibrexafungerp) – New drug approval June 2, 2024 - SCYNEXIS announced the FDA approval of Brexafemme (ibrexafungerp), for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC). Download PDF Return to …

Michigan Preferred Drug List (PDL)/Single PDL - Magellan Rx …

WebPrior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. QL: Quantity Limits Drugs that have quantity limits associated with each prescription. WebBrexafemme® Drugs- Brexafemme® (ibrexafungerp) [Scynexis, Inc.] April 2024. Therapeutic area - Antifungals, Oral. Initial approval criteria. Patient must have a diagnosis of vulvovaginal candidiasis AND; Patient is not pregnant AND; Patient is at least 18 years of age or patient is less than 18 years of age and post menarche AND start lifting weights at 50

Montana Medicaid Preferred Drug List (PDL) Revised April 10, …

WebPRIOR AUTHORIZATION. Clinical Information: Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial? Yes No. Has patient had at least one course of topical antifungal therapy? Yes No Please submit dates. Has patient had at least 2 courses of oral fluconazole 150mg? WebJun 7, 2024 · The one-day medication is the first non-azole oral treatment for vaginal yeast infection, and marks the first approved drug in a new antifungal class (triterpenoid) in more than 20 years. The... Web229 rows · The Food and Drug Administration (FDA) approved Brexafemme® … start lever on lawn mower